green valley-wepoker官网

wepoker-微扑克官网-纵横扑克之道
about us
about us
green valley is an innovative chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
about green valley
our business
mission & vision
our culture
code of business ethics
gv-971
gv-971
here you can get access to more information of gv-971.
products
news reports
research highlights
milestones
scientific research information
scientific research information
originality is the soul of our innovation in scientific research. we are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
life sciences innovation
research parteners
news
news
here you can get access to the latest news reports of green valley.
press releases
news reports
social responsibility
careers
apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. we respect, appreciate and reward the contributions of every employee for their hard work and dedication.
salary and benefits
contact us
contact us
media contacts
wepoker-微扑克官网-纵横扑克之道
news reports
news reports
products
news reports
research highlights
milestones
products
news reports
research highlights
milestones
10-25
2018
novel drug treatment shows improved cognition in a phase 3 clinical trial in persons with mild-to-moderate alzheimer's disease in china
green valley pharmaceutical co., ltd. (headquarter: shanghai) announced promising findings from a phase 3 clinical trial of gv-971, a multi targeting carbohydrate-based drug, with 818 patients across 34 sites in china for treatment of patients with mild-to-moderate alzheimer’s disease at the 11th clinical trials on alzheimer’s disease conference (ctad) in barcelona, spain.
10-25
2018
gv-971: spearheading global drug development for alzheimer's disease with a new perspective
on oct.25th 2018, in the middle of the 11th clinical trials on alzheimer’s disease conference held in barcelona, the green valley scientific advisory committee was formally established, and thereupon held its first meeting, where 16 top ad experts including jeffrey cummings, eric reiman, bruno dubois, martin farlow, jacques touchon, zhang zhenxin, xiao shifu, and chen biao, attended the discussion.
10-26
2018
green valley and international scientists join hands to fight against alzheimer's disease, leading global endeavor with innovation hailing from china
on the evening of november 26th 2018, a cocktail reception was organized by green valley during the 11th clinical trials on alzheimer's disease conference. at the reception, dr. jeffrey cummings, director of the cleveland clinic lou ruvo center for brain health, and dr. eric reiman, executive director of banner alzheimer's institute, among other distinguished ad drug development experts present, gathered with gv-971 r&d team, led by dr. meiyu geng, key inventor of gv-971 and professor at shanghai institute of materia medica, to celebrate great achievements gained by this chinese research team, and to envision a bright future where innovation hailing from china benefits patients across the whole world.
07-17
2018
an innovative anti-alzheimer's disease drug from china meets the primary endpoint of a phase 3 clinical trial
shanghai green valley pharmaceutical co., ltd. (green valley) today announced that its phase 3 study of sodium oligomannurarate (gv-971) capsule on mild-to-moderate alzheimer’s disease (ad) met its primary endpoint. gv-971 was co-discovered and co-developed by ocean university of china (ouc), shanghai institute of materia medica (simm) of chinese academy of sciences and green valley. after over 21 year comprehensive investigation, gv-971 is the first multi-targeting and carbohydrate-based drug for the treatment of ad in the world.
11-21
2018
good news | gv-971, chinese great achievement in novel ad medicine development, grabs lots of attention from chinese and international media
at the 11th clinical trials on alzheimer's disease conference on oct. 25, dr. meiyu geng, key inventor of gv-971 and professor at shanghai institute of materia medica, chinese academy of sciences, presented key findings from a phase 3 clinical trial of sodium oligo-mannurarate (gv-971) for mild-to-moderate alzheimer’s disease on behalf of the research team and green valley. it was highly applauded by the audience on the scene and was highly recognized by ctad scientific committee members.
11-20
2018
alzforum | fits and starts: trial results from the ctad conference
as in years past, trial results offered up a mixed bag of goods and duds at the clinical trials on alzheimer’s disease conference, held october 24–27 in barcelona, spain. in the first phase 3 ad trial ever conducted in china, a seaweed oligosaccharide was claimed to have halted or even reversed the slide into dementia of people with mild to moderate alzheimer's.
10-30
2018
the pharmaletter | chinese answer to alzheimer's puzzle?
evidence of an effective new treatment for alzheimer's would create shock waves across healthcare given the extent of the global need among millions of patients.
10-25
2018
medscape news | positive topline results for novel alzheimer's drug
a novel drug is showing promise for helping improve cognition in patients with mild to moderate alzheimer's disease (ad), according to new topline results.
网站地图